KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $23.80.

Several research analysts have recently weighed in on KALV shares. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Finally, Bank of America assumed coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target for the company.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par acquired 43,707 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was purchased at an average price of $8.76 per share, with a total value of $382,873.32. Following the acquisition, the insider now directly owns 4,986,480 shares of the company’s stock, valued at approximately $43,681,564.80. This trade represents a 0.88 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,627 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the transaction, the chief executive officer now directly owns 274,596 shares in the company, valued at $2,677,311. This represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders bought 236,055 shares of company stock valued at $2,162,146 and sold 15,856 shares valued at $155,172. 10.50% of the stock is currently owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP raised its stake in KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after purchasing an additional 1,700,000 shares in the last quarter. Boxer Capital Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $13,467,000. Octagon Capital Advisors LP bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $11,604,000. Frazier Life Sciences Management L.P. boosted its position in shares of KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock worth $41,400,000 after acquiring an additional 1,200,000 shares in the last quarter. Finally, Stempoint Capital LP bought a new position in KalVista Pharmaceuticals in the fourth quarter valued at approximately $8,409,000.

KalVista Pharmaceuticals Trading Up 3.2 %

KALV opened at $10.35 on Tuesday. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $15.50. The firm has a 50-day moving average price of $8.89 and a two-hundred day moving average price of $10.36. The stock has a market capitalization of $511.48 million, a PE ratio of -2.84 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, research analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).